Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

News and Trends 2 Sep 2016

Roche rockets into Checkpoint Inhibitor space with Phase III Lung Cancer Success

Tecentriq could be Roche’s ticket to the top of immuno-oncology. The checkpoint inhibitor just reached its co-primary endpoints in Phase III trials for non-small cell lung cancer and could bring the company €4.5B. Roche’s Tecentriq (atezolizumab) has demonstrated that it is a force to be reckoned with by clearing Phase III clinical trials for non-small cell […]

September 2, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 2 Sep 2016

Vienna-based Themis Bioscience frontlines vaccine development against emerging diseases

From Switzerland, we depart once again, this time for Vienna. This week, we are visiting Themis Bioscience, our Biotech of the Week (and also stopping for schnitzel). City: Vienna, Austria Founded: 2009 Employees: 4 Financial Data: €10M Total Raised (as of 12/2015) CEO: Erich Tauber Mission: Themis Bioscience targets emerging diseases, like Zika and Chikungunya, and aims to develop […]

September 2, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 2 Sep 2016

This €18M Joint Venture could Scale Up Bioplastic Film Production

Roughly 300 million tons of plastic are produced globally every year, but only 700 thousand tons are bio-based and biodegradable. Carbios’s new Joint Venture aims to dramatically grow this market. Carbios has announced the formation of CARBIOLICE, a new French joint venture shared between it, Limagrain Céréales Ingrédients (a heavyweight in the field of mulching films) […]

September 2, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 1 Sep 2016

Infographic: How Cancer Starts & How It Chooses Organs

Here’s a neat infographic from Cancer Research UK summarizing a new Cell report from UK researchers that describes how conditions build to trigger cancer. This information would help to explain the greater vulnerability of certain organs to tumors compared to others. The team, headed by Richard James Gilbertson, demonstrated that while cells may start with equal carcinogenic risk, tumor […]

September 1, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 1 Sep 2016

Cevec: “Our Special Cell Lines will help the next generation of Gene Therapy”

Cevec could very well be the missing link between adenoviral vectors and approved gene therapies. I had a chat with the CSO of Cevec about what makes its technology great and how it’s ready for the future of gene therapy. Gene therapy is one of the strongest trends in biotechnology right now. The field has […]

September 1, 2016 - 6 minutesmins - By Denise Neves Gameiro

News and Trends 1 Sep 2016

GSK is Advancing a Revolutionary Dual HIV Therapy

Gilead has long been the leader in HIV treatments, but GlaxoSmithKline’s CEO revealed to the WSJ that the company has been investing in the field. It could give Gilead a run for its money with dolutegravir, a new integrase inhibitor so powerful it may knock the standard down from triple to dual therapy. Since the […]

September 1, 2016 - 3 minutesmins - By Evelyn Warner

ADVERTISEMENT

News and Trends 31 Aug 2016

Novartis’ second FDA Biosimilar Approval could unlock Billions

Novartis just attained FDA approval for a second biosimilar in the US. Erelzi will unlock the €4.5B rheumatoid arthritis market cornered by Enbrel. Sandoz, a division of Novartis based in the Munich area, has taken home another trophy from the biosimilar battleground by scoring a second FDA approval for its copycat, Erelzi (etanercept-szzs). This drug mimics Enbrel, a €4.5B franchise managed by Amgen in the US that treats rheumatoid arthritis as well […]

August 31, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 31 Aug 2016

World’s most advanced Artificial Heart started its last Study before Approval

This artificial heart could replace any defective heart. It’s being developed by the French company Carmat, which just started the last clinical phase before market approval. Carmat is solving one of the life-long problems for humans, how to replace a broken heart. It’s not the first to offer a solution (e.g. Robert Jarvik in the US), […]

August 31, 2016 - 3 minutesmins - By Philip Hemme

News and Trends 31 Aug 2016

Discover the best Refresh Program we’ve ever made!

Hi there, I’m excited to show you what we have been cooking for our next Labiotech Refresh event in Paris on Nov 24th. We’ve been working hard on bringing in top-notch speakers to build up what we think is our most exciting program so far. Some of the highlights include a Keynote of French Biotech […]

August 31, 2016 - 1 minutemin - By Philip Hemme

News and Trends 31 Aug 2016

No Tumour, No Cancer Cure: New Epigenetic Test can pinpoint Elusive Ones

Not all tumours are detectable, which makes them particularly deadly. Researchers at the University of Barcelona have developed an epigenetic test to find them, the first of its kind to diagnose tumour sources. Cancer starts with a tumour, which grows and eventually sheds cells. These cells lodge in other tissues in the body and grow […]

August 31, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 30 Aug 2016

New non-amphetaminic ADHD drug ‘speeds’ into Phase II

ADHD is believed to affect up to 7% of people worldwide, but some common therapies bear a shocking resemblance to Speed. A new drug from NLS, Mazindol, just entered Phase II and could set a new non-amphetaminic standard. The treatment of Attention Deficit Hyperactive Disorder (ADHD) is hotly debated in the US, were almost 10% […]

August 30, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 30 Aug 2016

Mice made Transparent to reveal Brain and Blood Networks

uDISCO could be the name of Munich’s newest, hottest club. Indeed, it stands for ‘ultimate DISCO’ and boasts mesmerizing green lights. But it’s actually something much more exciting: it’s a new method that renders mice transparent to improve anatomical imaging. A team of researchers headed by Prof. Ali Ertürk at Ludwig Maximilian University in Munich, […]

August 30, 2016 - 2 minutesmins - By Evelyn Warner

ADVERTISEMENT